Drug intelligence / Profile preview

INCB000631

Development stage: Phase 1
Lead developer: Incyte
Modality: Small Molecules
Administration: Oral

Overview

INCB000631 is an investigational small molecule drug developed by Incyte for currently undisclosed indications. As of June 2025, it is in early clinical development (Phase 1), with studies focused on evaluating its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effect when administered orally to healthy adult participants. The precise mechanism of action and therapeutic targets have not been disclosed publicly. There are no approved indications or known adverse events reported at this stage[1][2][3][4][5].

Other names: INCB 000631INCB000631INCB-000631

Beyond the preview

Go deeper on INCB000631.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCB000631.

Explore the full profile